• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Glykolipide mit zell- und geweberegenerierenden Eigenschaften werden aus Blut oder Organhomogenisaten von Säugetieren gewonnen, indem das Ausgangsmaterial einer Autolyse und einer Dialyse gegen ein alkoholischwäßriges Medium unterworfen wird. Aus dem erhaltenen Rohprodukt können die Glykolipide durch Äthanolausfällung oder Extraktion und danach Chromatographie isoliert und gereinigt werden. Das Verfahren ergibt höhere Ausbeuten an Wirkstoffen; es eignet sich zur industriellen Anwendung vorzüglich.
    公开号:SU1396958A3
    申请号:SU833598349
    申请日:1983-05-27
    公开日:1988-05-15
    发明作者:Фраэфель Вольфганг；Чаннен Роланд
    申请人:Золько Базель Аг (Фирма)；
    IPC主号:
    专利说明:

    with
    SO O5
    coke
    00

    cm
    The invention relates to medicine, in particular to methods for producing compounds that accelerate wound healing,
    The purpose of the invention is to increase the yield of the target product.
    PRI me R 1.
    but. 2 l of the blood obtained from the slaughter bodies is immediately mixed at the slaughterhouse with 300 MP of ethanol and treated with a bacteriostatic agent, methyl p-hydroxybenzoate (methyl paraben) and p-hydroxybenzoic acid n-propyl ester (propyl-paraben) to a concentration of each of them is 0.02%. The blood treated in this way will autolise for three days at room temperature. In this case, there is a strong hemolysis and partial decomposition of the unstable components, as well as the dissolution of the components passing through the membrane. The resulting autolysate is separated from the precipitate by decantation, and the supernatant
    subjected to a three-day dialy-25 zhani source material.
    through a membrane that does not allow compounds with a molecular weight greater than 10,000, in a static or dynamic manner. In the case of dynamic dialysis, the dialysate and the anti-dialysate are pumped through the membrane for three days with a pump to maintain the maximum concentration gradient. In this process, blood is simultaneously autolized and the resulting autolysis products can continuously diffuse through the dialysis membrane. In order to correctly maintain an optimal level of concentration at each time point, the passing autolysis is carried out in countercurrent.
    The resulting antidialysate or filtrate has a dry matter content of 5-80 mg / mp. The content of the compounds promoting the healing of wounds reaches 1 mg / MP (by a known method, a product with a content of glycosphingolipids of 0.005 mg / ml is obtained)
    b. The filtrate is mixed with 6 l of a mixture of ethanol and ether in a ratio of 3: 1. In this case, a sediment containing mainly glycosphingolipids is depressed. The precipitate is centrifuged in a centrifuge at an acceleration of 18,000 g for 30 minutes and separated from the liquid phase.
    The precipitate obtained is dried under vacuum at which time it is dissolved in 20 ml of a mixture of chloroform and methane.
    Nola in the ratio of 65:35. Dissolved glycosphingolipids are passed through a florisil (trade name gel silica gel of the highly selective adsorbent from Florini Corp of Pittsburgh, Pennsylvania, USA) filled with a column with a diameter of 5.0 cm and a height of 40 cm using a chloroform / methanol ratio of 65:35 as the mobile phase resulting in the removal of phospholipid residues. Glycosphingolipids are eluted from the column successively with mixtures of chloroform and methanol, 2 l each, with a methanol content of 35, 50, 75% and, finally, 100% methanol. Compounds obtained in separate elution steps were tested for the ability to heal wounds. It turned out that the fractions of the compound contained in the latter, eluted with 100% methanol, accelerate wound healing. The yield is 18% of the content.
    35
    0

    0
    five
    The compounds contained in this fraction are applied to preparative plates for thin-layer chromatography with a silica gel coating of a thickness of 2 mm. Upward chromatography was carried out using a mixture of chloroform, methanol and O, a 1% aqueous solution of calcium chloride as a mobile phase in a ratio of 55:45:10. The distance is 18 cm. After chromatography, the plates are dried and briefly placed in a chamber with an atmosphere saturated with iodine vapor. The zones that are painted yellow in color are marked, after sublimation of iodine, silica gel is scraped off the plate and elution is carried out with a mixture of chloroform and methanol in a 50:50 ratio. In experiments on the accelerating effect on the healing of burn wounds in rats, positive results were obtained when using the fraction with the Rr value when the separation by the indicated thin layer chromatography method was equal to 0.65. I
    Example 2.2l of the antidialysis prepared in Example 1a is dried in a rotary evaporator or lyophilized and dissolved in 4 L of a mixture of tetrahydrophzfan and a 0.01 M solution of KCl in a 4: 1 ratio. The insoluble residue is filtered on a paper filter, and the clear solution is evaporated in a rotary vortex apparatus to a volume of
    500 MP, 1 L of a mixture of chloroform and methanol in a 2: 1 ratio is added to it and the organic and aqueous phases are separated by adding 200 ml of water to the mixture. The upper phase containing glycolipids is separated and evaporated to dryness. The dry residue is dissolved in 10 ml of a mixture of chloroform, methanol and water in
    the ratio of 90: 10: 0,2. The column is flushed-io in a 9: 1 ratio and these are discarded.
    1.5 l of a mixture of the same composition is added, after which the glycolipid is eluted from it in 1 l of a mixture of chloroform, methanol and water in a ratio of 85: 15: 0.2. Output
    is 21% of the content of the outcome - 15 Form. The yield is 41% of the material content, RC 0.65. The purified compound obtained by this method is a glycolipid, which accelerates the healing of burn wounds.
    Example 3,2l protivodiali-
    Zata, obtained in example 1A, is extracted as described in Example 16 with a mixture of ethanol and ether in a ratio of 3: 1 and the precipitate is a solution of Yoth in 20 ml of a mixture of chloroform and methanol in a ratio of 2: 8. Diethylaminoethyl-Sephadex A50 in the C1-form by washing with O, 1N. a solution of caustic soda and 1 and. the acetic acid solution is converted into the acetate form, washed with methanol, and the column is filled with a diameter of 2.5 and a height of 20 cm. The product is dissolved in a mixture of chloroform and methanol in 2: 8 ratios
    with t into the column and washed with its successively laminar flow, constantly removing 200 ml of 0.001 each, hydrolysis products that passed through the membrane.
    The result of this is that at each point in time an optimal concentration difference of 0, 002 and 0.2 M sodium acetate is created. After this, the glycolipid is eluted with a mixture of chloroform and methanol in a ratio of 2: 8. The yield is 48% of the content
    4Q
    starting material, Rr 0.65, the glycolipid eluted in this way accelerates the healing of burn wounds.
    Example 4 The antidialysate of example 1a is mixed with 9 volumes of ethanol and the mixture is stirred for 30 minutes at 85 ° C. The precipitate is filtered through a filter paper and the clear solution is kept at 3 ° C at 20 ° C. The precipitate of the target compound precipitates during this time. The supernatant is separated by decantation, and the residue is dissolved in a mixture of chloroform and methanol in a ratio of 2: 1 and the solution is transferred to a column filled with modified diethylaminoethyl sephacel) in an acetate form. Elution is carried out
    with a mixture of chloroform and methanol in a ratio of 2: 1, the eluant is collected, evaporated in a rotary evaporator and dissolved in chloroform. The solution is transferred to a column filled with activated carbon in chloroform. The column is washed first with chloroform, then with a mixture of chloroform and methanol
    eluates. After that, the column is washed with a mixture of acetone and methanol in a ratio of 9: 1. The desired glycolipid is contained in this fraction in pure
    reap of the starting material, RfS 0.65,
    Due to the use of autolysis and dialysis, the yield of glycolipids is significantly increased (up to 1 mg / ml compared to 0.005 mg / ml).
    In addition, only one chromatographic separation is used, while by a known method three chromatographic separations are required.
    If autolysis and dialysis are carried out simultaneously and continuously by the countercurrent method, then the efficiency of the method is further increased. Thanks to dialysis by the countercurrent method, the autolysate constantly takes low molecular weight hydrolysis products, since on the other side of the membrane, t, e, on the dialysate side,
    4Q
    of hydrolysis products between dialysis and membrane autolysis. Removal of these products further leads to the fact that hydrolysis on the side of the auto- membrane behind the membrane cannot reach equilibrium and, accordingly, gives complete hydrolysis of the target product, which is impossible with static ultrafiltration or static dialysis, since here an equilibrium is reached. of the target product and constant hydrolyzate. Using pharmacological experiments, it was shown that the obtained active substances promote the proliferation of pre-damaged fibroblasts in vitro and, in addition, obstvuyut regeneration respective cell populations in vivo
    In this case, we are not talking about the usual compounds that have a mitotic effect, since with the addition of the mentioned compounds to normal healthy cell cultures, no changes occur, but a culture with a normally low degree of division caused by the addition of harmful agents to them. these compounds in a short time again restore their functions in relation to the degree of division, which are almost identical to the corresponding function of a healthy culture.
    Taking into account the fact that the reducing mechanisms of cell populations, both in vitro and in vivo, are stimulated by compounds obtained by the proposed method, the latter can be recommended for therapeutic use, particularly in the treatment of slow or poor healing of wounds or ulcerations, whose restorative abilities are limited. The beneficial effects of these compounds on wound healing are illustrated by the following animal experiments.
    Opp 1. Narcotized rats are shaved off their hair and on both sides of the body they cause burn wounds by applying to the bare skin 30 brass disks 2 cm in diameter heated to 270 ° C. The active substance is introduced into the iron base. The result is an ointment with a 20% active substance content. For comparison, a control ointment is prepared by administering table salt into jelly, water, or saline. Two batches of experimental animals (10 animals in each batch) daily (twice a day) are treated with wounds with ointment until they are completely healed. In the case of the compound described in Example 2, with an R value of 0.65, the cure time is reduced compared to the control group, and this reduction can go up to 21%. .
    Test 2. Narcotized rats were applied by stamping a wound with a width of 1 cm and a depth of 5 mm. Hollow cylinders with a viscose-cellulose sponge are introduced into the wound apertures. Every day, 100 µl of the purified compound is injected into the internal cavity of the cylindrical tube. Through 4, 10, 16 and 2
    the day after the start of implantation, the sponge is removed and analyzed for hemoglobin, deoxyribonucleic acid and hydroxypyroline content. The content of these compounds in implanted sponges removed from wounds 4 and 10 days after the start of the introduction of pure compounds was no higher than in sponges removed from wounds of control animals. However, after 16 and 21 days, the content of deoxyribonucleic acid and oxypyroline in the sponges of hemoglobin was significantly higher.
    Thanks to the purified compound in accordance with Examples 1-4, wound healing is accelerated at an early stage of formation of the stroma and the basal layer with capillaries.
    Experience 3. The growth of cell cultures, such as growing fibroblasts, can be slowed down by removing sodium carbonate from the nutrient medium. The addition of the compounds described in examples 1-4 to the nutrient medium causes the cells to recover their functions more quickly. Their normal division rate is achieved faster than that of similarly inhibited, but not subjected to additional processing of cell cultures.
    权利要求:
    Claims (3)
    [1]
    1. The method of obtaining glycolipid derivatives that stimulate the regeneration of cells and tissues by extracting the active principle from the blood of the calf, followed by chromatography, which is characterized by the fact that, in order to increase the yield of the target product, blood is spent for 3 days at room temperature and dialysis through a membrane with a limit of dissolution of the LLC with respect to an aqueous-alcoholic medium, the dialysate and the dialysate being continuously pumped in a counter-current pump or the autolysate is separated by decantation from the precipitate. followed by dialysis of the supernatant, then a mixture of ethanol and ether in a ratio of 3: 1 is added to the antidialysate, the precipitate obtained is centrifuged at 18000 g for 30 minutes, dried and dissolved in a mixture of chloroform and methanol in a ratio of 65:35 and elution carried out with a mixture of chloroform and methanol with increasing concentration
    methanol, and as a mobile phase in chromatography of the active fraction, a mixture of chloroform, methanol and an aqueous solution of calcium chloride in a ratio of 55:45:10 is used.
    [2]
    2. A method of obtaining glycolipid derivatives that stimulate the regeneration of cells and tissues by increasing the active principle from the blood of the calf, followed by chromatography, characterized in that, in order to increase the yield of the target product, the blood is autolysis for 3 days at room temperature. temperature and dialysis through a membrane with a dissolution limit of 10,000 relative to an aqueous-alcoholic medium, the dialysate and the dialysate being continuously pumped over with a pump in countercurrent or the autosate is separated by decanter the precipitate followed by dialysis of the supernatant, then the antidialysate is dried and dissolved in a mixture of tetrahydrofuran and an aqueous solution of potassium chloride in a ratio of 4: 1, the solution is filtered and evaporated, the concentrate is mixed with a mixture of chloroform
    and methanol in a ratio of 2: 1, is separated into organic and aqueous phases by adding water, the supernatant organic phase is separated, followed by drying and dissolving in a mixture of chloroform, methanol and water in a ratio of 90: 10: 0.2, and chromatography is carried out t on a Bio-Sil-A column with the same solvent mixture.
    [3]
    3. A method of obtaining glycolipid derivatives that stimulate cell and tissue regeneration by increasing the active principle from the blood of the calf, followed by chromatography, characterized in that, in order to increase the yield of the target product, blood is autolysis for 3 days at room temperature. temperature and dialysis through a membrane with a limit of dissolution of U LLC in relation to water-alcohol, medium,
    Editor M. Petrov
    ten
    20
    25
    the autolysate and antidialysate are continuously pumped in a countercurrent pump, or the autolysate is separated by decantation from the precipitate, followed by dialysis of the supernatant, the antidialysate is mixed with 9 volumes of ethanol and stirred at and the residue is dissolved in a mixture of chloroform and methanol in a 2: 1 ratio, and the chromatography is carried out in a column filled with a modified diztilamino-ethyl sephacel in an acetate form with the same solvent mixture, whereafter the zlyuirovanie mixture of chloroform: methanol = 9: 1 and then a mixture of acetone with methanol in the same ratio.
    4, the method of obtaining glycolipid derivatives stimulating the regeneration of cells and tissues by dissolving the active principle from the blood of the calf, followed by chromatography, characterized in that, in order to increase the yield of the target product, the autolysis of the blood is carried out for 3 days at room temperature and dialysis through a membrane with a dissolution limit of 10,000, relative to an aqueous-alcoholic medium, while dialysate and antidialysate are continuously pumped using a pump in countercurrent or autoclave are separated by decantation from cage with posledukmtsey daalizahschey supernatant to protivodializu then added a mixture of ethanol and ether at a ratio of 3: 1, the resulting precipitate was separated by centrifugation at 18,000 g for 30 min, dried and dissolved with a mixture of chloroform and methanol The relationships. 2: 8, and the solution was chromatographed on a column filled with diethylaminoethyl-sephadex A50 in an acetate form, and elution was carried out with a mixture of chloroform and methane (la in a ratio of 2: 8).
    Compiled by L. Shilina
    Tehred L. Serdyukova Proofreader A.Obruchar
    thirty
    35
    40
    45
    50
    ten
    five
    20
    five
    25
    thirty
    35
    40
    45
    50
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1396958A3|1988-05-15|Versions of method of producing derivatives of glicolipids stimulating regeneration of cells and tissue
    US2320479A|1943-06-01|Topical remedy
    Dalziel1958|On the purification of liver alcohol dehydrogenase
    Bartels et al.1970|Prostaglandin: liberation from and formation in perfused frog intestine
    US4456596A|1984-06-26|Wound healing glycoside compositions
    US4599176A|1986-07-08|Process for the production of cell stimulating agents
    EP0038511B1|1985-01-16|Wound healing compositions
    EP0029893B1|1987-05-20|Process for concentration of tumor-inhibiting substances
    EP0035102B1|1983-10-19|Oligopeptide selectively inhibiting the growth or multiplication of normal and leukaemic myeloid cells, to be isolated from healthy white blood cells or granulocytes, process for its preparation, and medicaments containing it
    ES437046A2|1977-05-16|Manufacture of novel amino acid derivative
    Curtain et al.1963|The isolation from human blood plasma of a substance having positive inotropic action on the isolated toad heart
    US4908206A|1990-03-13|Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them
    Duwe et al.1978|Regulation of DNA synthesis and antibody production by soluble factors released by bone marrow cells
    US3466367A|1969-09-09|Preparation of growth regulating compositions comprising thymus extracts
    US4139611A|1979-02-13|Organic peptide containing substance recovered from blood having insulin-like activity
    CN104628889A|2015-05-20|Extraction method of heparin sodium
    GLASS et al.1961|The estrogenic properties in vitro of diethylstilbestrol and substances related to estradiol
    US2101099A|1937-12-07|Manganese compounds of nucleotides and of their hydrolytic decomposition products
    RU2053777C1|1996-02-10|Composition for osteogenesis activation
    RU2078345C1|1997-04-27|Method of preparing serum protein preparations influencing activity of oxidative energetic exchange
    RU2182007C1|2002-05-10|Granulomonocytopoiesisstimulating preparation at hypoplastic states of blood formation
    DK161153B|1991-06-03|PROCEDURE FOR THE PREPARATION OF AN APPEARANCE REGULATING ACTIVE SUBSTANCE, SATIETIN D, FROM HUMAN AND / OR ANIMAL BLOOD SPACES
    RU2159623C1|2000-11-27|Medical preparation for treating and repairing varicose veins, healing ulcers, wounds, fissures, hemorrhoids, cleaning and restoring intestine tract epithelium layer, improving organism functioning as a whole
    SU1716450A1|1992-02-28|Method for determination hemoglobin heterogeneity
    OHKUMA et al.1969|Sialoglycopeptides released by ficin from human erythrocytes
    同族专利:
    公开号 | 公开日
    DK157763C|1990-07-09|
    PL242228A1|1984-07-02|
    AR231231A1|1984-10-31|
    DK231683A|1983-11-29|
    PL142242B1|1987-10-31|
    NO157144B|1987-10-19|
    ZA833446B|1984-02-29|
    YU44865B|1991-04-30|
    HU189286B|1986-06-30|
    AU1499483A|1983-12-01|
    CA1202894A|1986-04-08|
    NO831894L|1983-11-29|
    DD209736A5|1984-05-23|
    JPS58219120A|1983-12-20|
    FI77373B|1988-11-30|
    US4544552A|1985-10-01|
    FI831827L|1983-11-29|
    AT29137T|1987-09-15|
    YU110483A|1986-02-28|
    DK231683D0|1983-05-24|
    EP0095682A3|1984-06-13|
    FI77373C|1989-03-10|
    ES8407064A1|1984-08-16|
    DE3373188D1|1987-10-01|
    FI831827A0|1983-05-23|
    AU551992B2|1986-05-15|
    ES522758A0|1984-08-16|
    EP0095682A2|1983-12-07|
    NO157144C|1988-01-27|
    DK157763B|1990-02-12|
    EP0095682B1|1987-08-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2912359A|1955-05-04|1959-11-10|Developments Inc|Wound healing agent obtained from blood and method of preparation|
    US3526697A|1966-10-06|1970-09-01|Nevada Pharm Inc|Therapeutic method|
    JPS5220524B1|1968-11-02|1977-06-04|
    LU62266A1|1970-12-17|1972-08-23|
    FR2195425B1|1972-08-10|1977-02-25|Manganaro Domenico|
    CA1168980A|1980-04-17|1984-06-12|Rolf Schafer|Wound healing compositions|US4699788A|1984-08-20|1987-10-13|Trustees Of Boston University|Angiogenic factor methods of extraction and method for producing angiogenesis|
    US4710490B1|1985-10-01|1989-08-29|
    US4767746B1|1985-12-04|1990-05-08|Angio Medical Corp|
    US4990333A|1985-12-20|1991-02-05|Angio Medical Corporation|Method for healing bone damage|
    US4778787A|1985-12-20|1988-10-18|Trustees Of Boston University|Method for treatment of angina and myocardial infarctions with omental lipids|
    US4816450A|1986-09-15|1989-03-28|Duke University|Inhibition of protein kinase C by long-chain bases|
    US4937232A|1986-09-15|1990-06-26|Duke University|Inhibition of protein kinase C by long-chain bases|
    US5019087A|1986-10-06|1991-05-28|American Biomaterials Corporation|Nerve regeneration conduit|
    EP0274547A1|1986-12-18|1988-07-20|Trustees Of Boston University|Method for enhancement of healing of epithelial wounds in mammals|
    WO1989002733A1|1987-09-22|1989-04-06|The Regents Of The University Of California|Liposomal nucleoside analogues for treating aids|
    US5035901A|1987-10-09|1991-07-30|University Of Kansas|Bone inducing agent from a human osteosarcoma cell line|
    US5693620A|1991-07-31|1997-12-02|Oncomembrane, Inc.|Plasmalopsychosines and plasmalocerebrosides|
    CA2111113A1|1991-07-31|1993-02-18|Edward Nudelman|Plasmalopsychosines and plasmalocerebrosides and methods of treating neuronal diseases employing the same|
    EP0645135A1|1993-09-29|1995-03-29|Solco Basel AG|Sunscreen composition containing hemodialysate|
    AU2606002A|2000-12-08|2002-06-18|Childrens Memorial Hospital|Compositions containing gangliosides for use in the treatment of skin disorders|
    WO2006121803A1|2005-05-05|2006-11-16|Sensient Flavors Inc.|Production of beta-glucans and mannans|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH332882|1982-05-28|
    [返回顶部]